What payment terms are accepted?

We accept LC (Letter of Credit) and T/T (Telegraphic Transfer) payments.

How long is the lead time during peak season?

The average lead time during peak season is one month.

Which ports are nearest for export?

The nearest ports are Tianjin Xingang, Qingdao, and Shanghai.

Lidocaine Hydrochloride Injection Lidocaine Infusion

Name: Lidocaine Hydrochloride Injection Lidocaine Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2128515835

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.16-0.26

100,000 Pieces

Sample price:US$0.25/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

5ml, 10ml

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

50ampoules/Box

Specification

5ml/ampoule

Origin

China

HS Code

30049090

Production Capacity

1000000pieces/Year

Key features

Dual Therapeutic Action: Functions as both a local anesthetic and an anti-arrhythmic drug for various medical conditions.

Broad Anesthesia Applications: Suitable for infiltration, epidural, topical, and nerve block anesthesia in adults, children, and the elderly.

Cardiac Arrhythmia Treatment: Effective for ventricular premature contractions, tachycardia, and arrhythmias caused by digitalis poisoning.

GMP Compliant Manufacturing: Produced in strict accordance with GMP requirements using full automation and international advanced technology.

Established Manufacturer: Shijiazhuang No. 4 Pharmaceutical Co., Ltd. has a 70-year history as a leading Chinese pharmaceutical brand.

Global Market Reach: Products exported to over 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Multiple Dosage Forms: Available in 5ml and 10ml ampoules for various injection and infusion needs.

Flexible Payment Terms: Accepts LC and T/T payment methods for international trade transactions.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤9.50hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.